Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute’s innovative drug development initiative-Group 3 pulmonary hypertension

By sjmartinez • July 1, 2022

Nikkho SM, Richter MJ, Shen E, Abman SH, Antoniou K, Chung J, Fernandes P, Hassoun P, Lazarus HM, Olschewski H, Piccari L, Psotka M, Saggar R, Shlobin OA, Stockbridge N, Vitulo P, Vizza CD, Wort SJ, Nathan SD. Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative-Group 3 pulmonary hypertension. Pulm Circ. 2022 Jul 1;12(3):e12127. doi: 10.1002/pul2.12127. PMID: 36016668; PMCID: PMC9395696.

Tags: Epidemiology, interstitial lung disease, prognosis, Publications, pulmonary hypertension, Pulmonary, Critical Care & Sleep Medicine, symptom assessment and management

Linking Baseline PSMA PET-Derived Parameters to Toxicity, Adverse Events, Pain, and Quality of Life in Patients Treated with [177Lu]Lu-PSMA-617: A Single-Center Retrospective Study

Murthy V, Kimura K, Theus L, Nguyen A, Grogan TR, Lokre O, Perk T, Rettig MB, Drakaki A, Shen J, Thin P, Nguyen K, Lira[...]

Disease-modifying effects of iron deficiency in mouse models of chronic renal failure

Zhang M, Lundin A, Jung G, Olivera JD, Sangkhae V, Sharma S, Ganz T, Nemeth E, Hanudel MR, Czaya B. Disease-modifying effects of iron deficiency[...]

Practice changing RCT design and rationale: Abbreviated MRI plus AFP vs. ultrasound plus AFP for HCC surveillance in cirrhosis (PREMIUM study)

Ioannou GN, Taddei TH, Planeta BM, Huang GD, Weiss NS, Morgan TR, Dominitz JA, Abou-Alfa GK, Bashir MR, Beheshti MV, Singal AG, Moylan CA, Boland[...]